



# Proteomics International

LABORATORIES LTD

ASX Release  
23 November 2023

ASX code: PIQ

## AGM Chairman's Address and Investor Presentation

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the Chairman's Address to be provided by Mr Neville Gardiner and the Investor Presentation to be provided by Dr Richard Lipscombe to shareholders at the Annual General Meeting to be held in Perth commencing at 9:30 am AWST today.

Authorised by Dr Richard Lipscombe (Managing Director) and Mr Neville Gardiner (Non-Executive Chairman) on behalf of the Board of PIQ.

ENDS

### About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Lisa Barnes  
Public Relations  
Profile Media  
T: +61 416 583 672  
E: [lisab@profilemedia.com.au](mailto:lisab@profilemedia.com.au)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

## Chairman's Address

Good Morning Ladies and Gentlemen

My name is Neville Gardiner, and as Chair of the company it is my pleasure to welcome you to the 9th Annual General Meeting of shareholders of Proteomics International Laboratories.

It is now after 9:30 am, and as we have a quorum of shareholders present, I declare the meeting open.

The notice convening today's meeting was made available to shareholders on the 23rd of October 2023 and lodged with ASX on that date. Consequently, I will take the notice as read.

Firstly, let me introduce the members of your Board:

In the Auditorium today are Dr Richard Lipscombe, Managing Director and Mr Paul House. Dr Robyn Elliott and Mr Roger Moore have joined the meeting online from interstate and overseas.

Also present here today are Ms Karen Logan, Company Secretary and Ms Jessica Rowe, representing BDO, our independent auditor.

I would like to especially welcome and acknowledge the many Proteomics team members that are here with us.

Richard will speak in more detail to the company's achievements in his presentation later this morning however I would like to take the opportunity to note that FY23 was a pivotal year for the company with the signing of full form documentation with Sonic Healthcare USA to bring our PromarkerD test to the United States. This was followed in more recent weeks with the announcement by the US Centers for Medicare & Medicaid Services of the proposed reimbursement price for PromarkerD in the United States.

While we were disappointed that the Australian Therapeutic Goods Administration decided not to include PromarkerD in the Australian Register of Therapeutic Goods we remain committed to delivering value for all our stakeholders by focussing our efforts on commercialising PromarkerD in the most relevant markets and advancing the very exciting pipeline of other Promarker tests.

We expect 2024 will be a year of continuing transformation of our company as the commercialisation of PromarkerD gains further momentum. With this in mind your Board and Management are constantly evaluating the skills and experience we need in the company to deliver on the foundations now laid for future success.

On behalf of the Board, I would like to thank Richard and the entire Proteomics team for their continuing professionalism and dedication. Their hard work has the potential to fundamentally improve millions of lives. I would also like to thank all our shareholders for their continuing support.

I will now turn to the formalities of the meeting.



# Proteomics International

LABORATORIES LTD

## AGM Presentation

*2023 – a pivotal year*

---

23 November 2023

**Dr. Richard Lipscombe**

Managing Director

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

A medical technology company at the forefront of precision medicine and predictive diagnostics

Three key focus tests driven by a proprietary platform technology:

**PromarkerD**

Diabetic Kidney Disease

COMMERCIALISATION

- Proven predictive test for early detection of diabetic kidney disease (DKD)
- Being commercialised & launched in the US by Sonic Healthcare USA
- US\$390 indicative test price & PIQ receives royalty for each test sold

**PromarkerEndo**

Endometriosis

DEVELOPMENT

- Test in development to diagnose Endometriosis
- Affects 1 in 9 women and costs Australia alone over AU\$10Bn a year
- Prototype test identified up to 90% of patients with the disease

**PromarkerEso**

Esophageal Cancer

DEVELOPMENT

- Test in development to diagnose Esophageal Cancer
- 1 in 20 cancer deaths worldwide due to oesophageal cancer
- Prototype test identified up to 90% of patients with the disease

## Corporate Snapshot (22/11/23)

ASX code	PIQ
Market Capitalisation	A\$116m
Cash (30 Sept 23 + \$1.85m R&D tax incentive received Q4 CY23)	\$4.9m

Share Price	A\$0.95
Shares on issue (+1.4m options)	122m

Revenue & other income – FY23	A\$3.3m
Average Quarterly cash burn – FY23	A\$1.55m



## Financial and Corporate

- Top 40 Shareholders hold 49%
- Directors are highly aligned with shareholders holding 18%
- Multiple institutional & family office shareholders on the register
- State-of-the-art laboratories
  - Accredited (ISO 17025 and ISO 13485) cutting-edge facility
  - Specialist proteomics technology platform
  - Analytical services – pharmacokinetic (PK) testing & biosimilars
  - Headquartered on QEII Medical Campus, Perth, WA
- Revenue generating
  - Bioanalytical service business helps offset cash burn
  - Current revenue does not include any major sales of PromarkerD

# Board of Directors



ASX: PIQ



## **Neville Gardiner** BBus (Accounting and Business Law) (Curtin), Non-Executive Chair

Seasoned finance professional with over 30 years' experience providing corporate advice to Boards of public and private companies. He was Co-Founder and MD of Torridon Partners, an independent corporate advisory firm, which was acquired by Deloitte in 2016, where he became Partner in their M&A Advisory team.



## **Dr Richard Lipscombe** PhD (London), MA (Oxon), Co-Founder & Managing Director

Led the Company from foundation through listing in 2015 to today. 30 years biotechnology experience in R&D and product commercialisation in academic and commercial entities. Technical expertise in chemistry, immunology, biomarker discovery & clinical proteomics.



## **Roger Moore** R (Denmark), BPharm (U.Syd), Non-Executive Director

International pharmaceutical industry experience spanning 40 years, including almost 30 years as President of Novo Nordisk Japan. From 2000, he was appointed Novo Nordisk's Senior Vice President, Japan & Oceania Region. He has also served as a member of the Senior Management Board, Novo Nordisk A/S.



## **Paul House** GAICD, BCommerce (UWA), Non-Executive Director

Over 25 years with multi-national corporations, CEO of Imdex (ASX:IMD), prior role as MD of SGS India for 8 years. Previously held CFO and COO roles, and was Senior Manager at a leading global management consultancy firm.




## **Dr Robyn Elliott** PhD Inorganic Chemistry (Monash), BSc(Hons) Chemistry (Monash), Non-Executive Director

Proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Dr Elliott is Executive Director, Strategic Fractionation Program Delivery at CSL Behring, a subsidiary of CSL Limited. She is also a non-executive director of PolyNovo Limited (ASX:PNV).



Promarker™ is a platform technology that can identify unique protein biomarkers ‘fingerprints’



The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests

# Promarker **D**

PROACTIVELY CHANGING RENAL HEALTHCARE

*A simple blood test for predicting diabetic kidney disease*



# Problem and Solution – Diabetic Kidney Disease



## The Problem


- **537 million adults** with diabetes globally
- **1-in-3** with diabetes have chronic kidney disease
- **Kidney disease is a silent killer** - kidney function can **fall below 15-20% with no symptoms**
- Damage to kidneys is **irreversible**, therefore **early detection** is paramount
- Diabetic kidney disease leads to renal failure which requires **dialysis (US\$72,000 p.a.) or kidney transplant**
- Total cost of diabetic kidney disease = **US\$130 Bn** per year in USA alone



Roadblock

## Current standard-of-care diagnostics

- Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present
- Current standard-of-care tests cannot **predict** the onset of diabetic kidney disease
- **If unchecked, patients ultimately require dialysis and/or a kidney transplant**



Diseased Kidney



Solution

## Promarker **D**

- PromarkerD can **predict** the onset of disease **before** clinical symptoms appear (up to four years prior)
- **Doctors can then prescribe an early therapeutic treatment to slow or stop the onset of disease**
- Kidneys remain healthier for longer, **saving healthcare systems billions of dollars and improving quality of life** for patients



Healthy Kidney

# PromarkerD: World Class Advisory Board

Proteomics International is supported by an international, highly acclaimed advisory board

**Professor Tim Davis** MedSc, MB, W.Aust., DPhil Oxf., FRACP, MRCP (UK) – *Australia*

Consultant physician and endocrinologist, Fremantle Hospital, Professor of Medicine, University of Western Australia; WA Health Department's Diabetes & Endocrinology Clinical Network Co-lead



**Dr Ele Ferrannini MD** – *Italy*

Professor of medicine, The University of Pisa  
Adjunct Clinical Professor of Medicine, University of Texas Health Science Center: Senior research associate, National Research Council's Institute of Clinical Physiology



**Ms Davida F. Kruger MSN, APN-BC, BC-ADM**  
– *United States*

Certified Nurse Practitioner, Henry Ford Health  
Past Chair of the American Diabetes Association's (ADA) Research Foundation; ADA Educator of the Year (2017)



**Dr Joshua Neumiller PharmD, CDCES, FASCP, FADCES**  
– *United States*

Professor of Pharmacotherapy, Washington State University  
Recipient of Albert B. Prescott Pharmacy Leadership Award (2016)  
ADCES Diabetes Care & Education Specialist of the Year (2021)



**Associate Professor Michael Shanik MD, FACP, FACE**  
– *United States*

Managing partner at Endocrine Associates of Long Island, PC  
Clinical Associate Professor, Stony Brook University Hospital, New York



**Dr Neil Skolnik MD** – *United States*

Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University  
Associate Director, Family Medicine Residency Program  
Jefferson Health



**Professor Merlin Thomas MBChB, PhD, FRACP, FAAHMS** – *Australia*

Nephrologist, scientist and program leader, the Department of Diabetes, Monash University  
Founder and Chief Scientific Officer, RAGE Biotech Ltd



**Dr Alexander Turchin MD, MS** – *United States*

Director of quality for the division of endocrinology, Brigham and Women's Hospital, Boston  
Associate Professor of Medicine, Harvard Medical School  
Fellow of the American College of Medical Informatics




**Ms Hope Warshaw MMSc, RD, CDCES, BC-ADM, FADCES** – *United States*

Registered Dietician, Certified Diabetes Care and Education Specialist  
President of the ADCES 2016 & Chair of the Academy's Foundation 2022-2023



# PromarkerD – Simple Integration & Use



Sample is drawn at clinic or pathology laboratory

Laboratory uses a standard technology platform

Advanced rapid immunoassay measures three plasma proteins -

*combined with* three simple clinical factors (age, cholesterol, eGFR)

CE Mark registered

Manufactured to ISO 13485 standard in Europe

Cloud based algorithm, the “PromarkerD Hub” calculates the patient’s kidney disease risk score

Employs a traffic light system for optimal performance, classifies patients as:

- low risk
- moderate risk
- high risk

Clinician delivers results to patient

Depending on results, intervention may include:

- change of lifestyle; and/or
- therapeutic drugs
  - SGLT2-inhibitor
  - GLP-1 agonist

# PromarkerD – Results & Intervention



ASX: PIQ

## How PromarkerD results are delivered



Prognostic **16%** indicates a **moderate** risk of decline in kidney function\*

Risk Score	Intervention	Testing Regimen
Low Risk	<ul style="list-style-type: none"> <li>Standard diabetes management</li> </ul>	Test Annually
Moderate Risk	<ul style="list-style-type: none"> <li>More frequent monitoring</li> <li>Optimisation of lifestyle</li> <li>Review of glycemic targets and management</li> <li>Review non-glycemic risk factors</li> <li>Avoidance of potentially nephrotoxic drugs</li> </ul>	Test every 6 months
High Risk	<ul style="list-style-type: none"> <li>Very close monitoring</li> <li>Intensive management strategies based on those for 'Moderate risk' above</li> <li>Utilisation of therapeutic drugs</li> </ul>	Test every 3 months

\*as defined by incident diabetic kidney disease (eGFR <60ml/min/1.73m<sup>2</sup>) in the next four years. Note: if eGFR level at the time of the test is already <60ml/min/1.73m<sup>2</sup>, then the risk of a further decline in kidney function is defined as an eGFR decline >30% in the next four years



# PromarkerD in the Clinic




ASX: PIQ



## Peer Reviewed

PromarkerD tested on **over 5,000 patients** in 4-year clinical studies

**10+ Peer Reviewed Publications**


World leading results: 

- Global clinical study 3,568 participants from completed CANVAS clinical trial
- PromarkerD predicted 'incident DKD' high-risk patients **13.5 times more likely** than low-risk to develop DKD ( $P = 1.3 \times 10^{-104}$ )

[J. Clin. Med. (2020)]

- PromarkerD **high-risk patients show greatest benefit** from early use of SGLT2-inhibitor

[J. Clin. Med. (2023)]



## Physician Support

**Survey of 400 Endocrinologists & Primary Care Physicians (US based)**


- **96% of physicians** were likely to use PromarkerD test scores for clinical decision making
- PromarkerD consistently ranked as **one of the top 2 factors** driving physician decision-making:
  - monitoring frequency
  - use of anti-inflammatories
  - prescribing SGLT2s
  - ACE inhibitor dosing

[PLOS One (2022)]



## Outperforms Standard of Care

- 857 community based patients tested for existing DKD at baseline: 497 had normal kidney function
- 9% of patients developed DKD within 4 years:
  - PromarkerD accurately predicted 84% (N=38)
  - All were missed by Standard of care tests [ASN (2021)]



PromarkerD compared to standard of care tests (eGFR and ACR) for predicting DKD

## PromarkerD

### The Need

There is a significant and growing need for intervention for diabetic kidney disease (DKD) across the globe

#### Economic Cost

- Kidney Research UK have declared a public health emergency - by 2033 kidney disease risks costing the UK Economy £13.9 billion annually
- Kidney Health Australia found the annual cost of Chronic Kidney Disease in Australia was A\$9.9 billion in 2021 – investment in early detection could yield a net benefit of \$10.2 billion over 20 years



### The Treatments

Patients identified as high-risk of DKD by PromarkerD now have multiple preventative treatment options:

#### Better management of diabetes

- Adherence to medications
- Focus on diet & exercise

#### New renal protective therapies

- Three **SLGT2-inhibitors** (empagliflozin, canagliflozin, dapagliflozin) have now been approved for treatment of DKD
- **GLP-1 agonist semaglutide (Ozempic)** trial for DKD shows treatment is renal protective



### The Utility

#### Complementary diagnostic

Early diagnosis of DKD using PromarkerD can help inform doctors' treatment decisions to improve clinical outcomes for patients:

- High-risk patients for kidney decline can be prescribed renal-protective medications such as SLGT2i or GLP-1ag
- Low-risk patients can avoid aggressive treatment options
- Monitor response and change dosage or drug type if required

Actions taken **BEFORE** the onset of DKD

# PromarkerD - Patented in all Major Markets




ASX: PIQ

Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally

Patent family & Trademark covers 72% of world's diabetics<sup>1</sup>

Country	Patent/Application No	Patent Status	No. Diabetics <sup>1</sup>
Australia	2011305050	Granted	1,491,800
Brazil	BR112013006740	Granted	15,733,600
Canada	2811654	Granted	2,974,000
China	ZL201180053583.9	Granted	140,869,600
Europe <sup>2,3</sup>	3151012	Granted	61,425,100
Hong Kong	18115912.3	Granted	686,000
India	3012/DELNP/2013	Granted	74,194,700
Indonesia	W00 2013 01585	Granted	19,465,100
Japan	2013-528474	Granted	11,005,000
Russia	2596486	Granted	7,392,100
Singapore	188527	Granted	711,800
<b>USA<sup>2,4</sup></b>	<b>US 9,146,243</b>	<b>Granted</b>	<b>32,215,300</b>
			<b>~368 million Total</b>



## Market assumptions

- Test is performed **once per year per patient** on average
- Standard industry **royalty rates range from 5-15%**


1. International Diabetes Federation (IDF) Atlas 10<sup>th</sup> Edition 2021 [Age group 20-79 years]  
 2. Australia, Europe, HK, USA patent family also covers testing for any form of kidney disease (Extra efficacy studies required)  
 3. Covers France, Germany, Italy, Spain, Turkey and the United Kingdom  
 4. USA patent further extended to cover method for identifying drugs for abnormal kidney function using one of the PromarkerD biomarkers (CD5L)

# United States: Commercialisation in Progress

Sonic Healthcare USA has the exclusive licence to commercialise PromarkerD in the world's largest healthcare market



**Over 7,000 Employees**  
**Over 300 Sales reps**  
**Over 400 pathologists**  
**Services over 20 million patients**



**Marketing, Sample collection, Reporting**



**PromarkerD Diabetic  
Kidney Disease Risk  
Assessment**

Early detection can significantly help prevent serious kidney damage.

**CLIA Certified Laboratories**

Sonic is the third Largest laboratory medicine company in the US



Test listed on Sonic website & commercial launch expected in Q1 CY24




Sonic has labs spanning from Hawaii to Boston




# Reimbursement in the US

Proteomics International has been working with its partner Sonic Healthcare USA to achieve reimbursement in the US



## US Reimbursement Timeline



# Target Markets: PromarkerD

Proteomics International is showcasing PromarkerD with KoL's at major conferences globally



**United Kingdom**  
4.8m T2 diabetics

- **Distribution Licence with Apacor Ltd** for PromarkerD
- Test registered with Medicines & Healthcare products Regulatory Agency
- *National Institute for Health & Care Excellence (NICE) Medtech Innovation Briefing "NICE Advice" published*

## Next Steps

- Engagement with the NHS Supply Chain Tender
- PromarkerD inclusion in the NICE guidelines
- MIB guide healthcare industry, enabling positive engagement with private healthcare providers



**Puerto Rico & Dom Republic**  
1.3m T2 diabetics

- **Licence with Omics Global Solutions** for immunoassay (Innovatio ND2) in Puerto Rico & Dominican Republic
- Test registered with Ministry of Health
- *First sales commenced*

## Next Steps

- Securing public reimbursement (Puerto Rico linked to CMS pricing)
- Expanding uptake of the test through engagement with primary care physicians
- *Exploring additional sales to neighbouring territories*



**Germany, France, Spain**  
15.1m T2 diabetics

- PromarkerD is CE Mark registered in Europe
- Germany, France and Spain are initial target markets
- Options to commercialise PromarkerD via:
  - Distributor Model; and/or
  - Licensing Model

## Next Steps

- Actively targeting potential partners in key jurisdictions



**Rest of World**  
316m+ T2 diabetics

- Detailed market assessments completed; discussions ongoing

## Next Steps

- Actively targeting potential partners in key jurisdictions

# Pipeline of Precision Diagnostics

Platform technology drives deep pipeline of novel diagnostic tests

## Further global potential in new markets

- Promarker™ platform develops novel intellectual property
- Targeting new diagnostic tests in areas of significant unmet need
- Enormous markets and revenue potential

### DIAGNOSTICS RESEARCH AND DEVELOPMENT – THE PROMARKER™ PIPELINE



# Dx Pipeline: Endometriosis


Potential world-first blood test in late-stage development

## Impact of Endometriosis

- Endometriosis is a common and painful disease where uterus tissue grows into other organs
- Currently **diagnosis takes an average of 7.5 years** and requires invasive surgery (laparoscopy)
- **Affects 1 in 9 women** and **costs Australia over AU\$10 billion a year** – global opportunity significantly higher

## Promarker™ for Endometriosis

- Prototype test identified up to **90%** of patients with the disease (World Endometriosis Conference, May '23)
- Collaboration with Royal Women's Hospital & University of Melbourne analysed 901 patients
- Biomarkers identified via the Promarker™ platform offer a **potential world-first blood test for endometriosis**
- **Next steps:** Accessing additional samples to confirm clinical performance – Pivotal results anticipated mid CY24



# Dx Pipeline: Oesophageal Cancer

## Potential world-first blood test in late-stage development

### Impact of Oesophageal Cancer

- **1 in 20 cancer deaths worldwide** due to oesophageal cancer  
- **5 year survival rate < 20%**
- Currently diagnosis requires a specialist endoscopy procedure; **treating the disease cost \$2.9bn in USA in 2018**
- Test targets oesophageal adenocarcinoma and Barrett's oesophagus (pre-malignant) which affects 1-2% of adults and can **arise from chronic acid reflux**

### Promarker™ for Oesophageal Cancer and Barrett's esophagus

- **Prototype test identified 90%** of people with & without the disease  
(World Congress Esophageal Diseases, Sept '23)
- Collaboration with QIMR Berghofer Medical Research Institute **analysed 302 samples**
- Results indicate a **potential world-first blood test to screen for oesophageal cancer**
- **Next steps:** PIQ has accessed samples from Victoria Biobank to confirm clinical performance – Pivotal results anticipated mid CY24

# Dx Pipeline: Oxidative Stress

## Potential world-first blood test in late-stage development

### What is Oxidative Stress?

- Oxidative stress occurs when the body's antioxidant defences are overwhelmed by an excess of toxic oxidants
- Oxidative stress is implicated in over 70 health conditions with **levels often reflective of a person's health condition**

### OxiDx – blood test to monitor oxidative stress

- OxiDx P/L was spun out of PIQ and the University of Western Australia in Aug 2022

### World first test:



- **Accurate** - highly sensitive
- **Simple to use** – finger prick sample
- **Cost effective** – for mass market use
- **Peer reviewed** – multiple journal publications
- **Patented** – USA, Australia and Japan granted, others pending



OxiDx

### Broad applications of OxiDx technology:

- **Athletic monitoring tool for competition preparedness:**
  - **Professional Sports** – performance, recovery and injury risk management – *55% of sports injuries are muscle related*
  - **Thoroughbred Racing Industry** – injury risk management and race-preparedness - *85% of Thoroughbreds suffer injury in their first 2-3 yrs*
- **Monitoring tool for health and wellbeing:**
  - **Precision Medicine** – tool for self-assessment
  - **Primary Industries** – monitor health in live export & stock production
- **Complementary diagnostic (CDx)**
  - **Clinical Trials** – Utilised to track treatment efficacy and personalised dosing in a range of indications




# Timeline & Milestones




ASX: PIQ

## FY23 Announcements & Achievements



## FY24 Targets & Milestones



# Value Inflection Points

## Exceptional Global Opportunity

- Disruptive, cutting-edge technology & proven in-house diagnostics platform
- PromarkerD test de-risked, patented, revenue ready
- Test rolling-out in easy-to-use, scalable, low cost format with high margins
- Whole of market appeal: pharma, clinical pathology labs, diagnostic platform developers, diabetes service providers, physicians and patients
- Deep pipeline of potential globally significant tests in development
- Vibrant corporate activity in the precision medicine, diagnostics and CRO (clinical trials) sectors

## Share Price Catalysts throughout FY24

Milestone	Qtr	Dec	Mar	Jun	Impact
<b>PromarkerD</b>					
First Sales in USA					Initiate pathway to significant revenues
CMS Reimbursement Pricing Set					Supports broad adoption of test
Regulatory Submissions, Approvals & Reimbursement RoW					Build user confidence in product & assist in global roll-out
Licensing Deals in RoW					Drive global uptake and future revenue
<b>Promarker™</b>					
Endometriosis Dx – updates					New first-in-class diagnostic test
Oesophageal Cancer Dx - updates					New first-in-class diagnostic test
Diagnostics Pipeline - updates					New IP (validation & proof of concept results)
<b>Analytical Services</b>					
New Contracts					Engages potential future partners & enhances revenue profile

## **Dr Richard Lipscombe**

**Managing Director**

T: +61 8 9389 1992

E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

[www.proteomicsinternational.com](http://www.proteomicsinternational.com)


## **Dirk van Dissel**

**Investor Relations & Corporate Advisor**

Candour Advisory

T: +61 408 326 367

E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)



**Proteomics International**

LABORATORIES LTD

## **Kyle Moss**

**Corporate Advisor**

Euroz Hartleys

T: +61 9488 1400

E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

# Supplemental

---



ASX: PIQ

# PromarkerD: Key Publications



<b>PromarkerD Demonstrates Benefit of Early Treatment with SGLT2-inhibitors</b>	Peters KE, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Score. J Clinical Medicine. <a href="#">2023</a> .
<b>Clinical Utility</b>	Fusfeld L, et al. Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis. PLOS ONE. <a href="#">2022</a> .
<b>PromarkerD vs Standard of Care</b>	Peters KE, et al. A Comparison of PromarkerD to Standard of Care Tests for Predicting Renal Decline in Type 2 Diabetes. Poster presented at ASN Kidney Week. <a href="#">2021</a> .
<b>Economic Health Benefit</b>	Burchenal W, et al. Demonstrating the Economic Health Benefit of using the PromarkerD In Vitro Diagnostic Test in the Prediction of Diabetic Kidney Disease. Poster presented at the American Diabetes Association's 81st Scientific Sessions. <a href="#">2021</a> .
<b>Global Multi-centre Validation</b>	Peters KE, et al. PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Journal of Clinical Medicine. <a href="#">2020</a> .
<b>Predicts Late-stage Renal Function Decline</b>	Peters KE, et al. PromarkerD Predicts Late-Stage Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Poster presented at ADA. <a href="#">2022</a> .
<b>Prognostic Validation</b>	Peters KE, et al. Validation of a Protein Biomarker Test for Predicting Renal Decline in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. J Diab Comp. <a href="#">2019</a> .
<b>Prognostic Development</b>	Peters KE, et al. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. <a href="#">2017</a> .
<b>Diagnostic Study</b>	Bringans SD, et al. Comprehensive Mass Spectrometry Based Biomarker Discovery and Validation Platform as Applied to Diabetic Kidney Disease. EuPA Open Proteomics. <a href="#">2017</a> .
<b>Cross-platform Validation</b>	Bringans SD, et al. The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease. Proteomes. <a href="#">2020</a> .
<b>Cross-over Validation</b>	Bringans SD, et al. A Robust Multiplex Immunoaffinity Mass Spectrometry Assay (PromarkerD) for Clinical Prediction of Diabetic Kidney Disease. Clin Proteomics. <a href="#">2020</a> .